Ricardo M. Camelo, MD, MBA, MSc, PhD, PostD

Professor
Department of Internal Medicine, Faculty of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil
Belo Horizonte, Minas Gerais, Brazil

Ricardo Mesquita Camelo is a Brazilian physician who has been studying rare diseases since 2003. He started studying rare bleeding disorders in 2017. He has MSc in Physiology and Pharmacology, PhD in Clinics, and PostD in Pharmacoeconomics. He is currently a Professor of Clinics at the Universidade Federal of Minas Gerais and the Faculdade de Ciências Médicas de Minas Gerais. He is involved in multicentric research in Brazil and other countries.

Presentation(s):

• OC 01.5 - People with mild hemophilia are at risk of joint disease: the nationwide cohort HiN-6 Study

  Saturday, June 22, 2024
  14:00 – 14:15 ICT

• PB0226 - Adherence and quality of life are not correlated in adolescent and adult men with hemophilia on factor replacement prophylaxis

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0227 - Cost evaluation of clotting factors concentrates before, during and after immune tolerance Induction according to outcome in Congenital Haemophilia A and inhibitor

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• PB0550 - Cost-effectiveness of prophylaxis with emicizumab or bypass agents in children with severe hemophilia A and high-response inhibitors after immune tolerance failure: a Brazilian perspective

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0551 - Girl with mild inherited hemophilia A and high-responding inhibitor associated with Melnick-Needles osteodysplasty syndrome: a case report of emicizumab prophylaxis effectiveness

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• PB0534 - Improved well-being in people with hemophilia A and inhibitor in emicizumab prophylaxis

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 41.1 - Cluster of deleterious variants in A3 domain of factor VIII in patients with haemophilia A and inhibitors

  Monday, June 24, 2024
  14:45 – 15:00 ICT

• PB1203 - Adherence to prophylaxis with clotting factors among people with hemophilia in a Brazilian Hemophilia Treatment Center

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1204 - Bleeds during the first year of emicizumab prophylaxis: preliminary results of the Brazilian Emicizumab Registry (EMCase Project)

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1217 - Erectile dysfunction is related to quality of life, but not to risk factors for cardiovascular diseases, among adult men with hemophilia

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1237 - Functional Independence in People with Hemophilia A on Emicizumab Prophylaxis

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1205 - Joint health in people with hemophilia A and inhibitors during emicizumab prophylaxis (EMCase Study)

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1188 - Pregnancy-associated Acquired Hemophilia A: A Systematic Review

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1265 - Switching prophylaxis during an immune tolerance induction evolving with failure: a case report from a Brazilian Hemophilia Treatment Center

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• PB1189 - Treatments and outcomes of acquired hemophilia A among women during the postpartum period: a systematic review

  Tuesday, June 25, 2024
  13:45 – 14:45 ICT

• OC 61.2 - Determinants of successful immune tolerance induction in people with severe hemophilia A

  Tuesday, June 25, 2024
  15:00 – 15:15 ICT